Welcome to the our Aesthetic Medicine news roundup, 14 August 2020.
Revance Moves Forward With 2 Botox Competitors
(AJMC) Revance received a milestone payment of $30 million from Mylan that fortifies the company in developing a biosimilar to Botox (onabotulinumtoxinA), and clinical trials are moving forward for a novel drug that also would compete with Botox, according to the company’s second quarter earnings report.
4 ways AI may change plastic surgery
(AI In Healthcare) It has a ways to go in the field, but AI promises to modernize plastic surgery along both its main branches, cosmetic and reconstructive.
Botox Antidepressant Effect Seen Across Range of Injection Sites
(Psychiatry and Behavioral Health Learning Network) Patients who received botulinum toxin injections at various sites for different conditions reported depression significantly less often, compared with patients undergoing different treatments for the same conditions, according to a study published in Scientific Reports.
The Pandemic Has Caused a Boom in Plastic Surgery
(Bloomberg) When no one can see your whole face, it’s the perfect time to get a little work done.
AMP
